Tocilizumab for Aortitis in Giant Cell Arteritis
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with giant cell arteritis (GCA) with active swelling of the aorta (aortitis) as seen on a scan like PET, CT, or MRI.
- You have not taken tocilizumab (Actemra) before and found it didn't work or you couldn't tolerate it.
- You have no active or recent cancer (within the last 5 years), no severe immune problems, and no serious kidney or liver issues.
- You are not pregnant or breastfeeding, and you use reliable birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called bosentan, which is usually used for other conditions, can help calm the inflammation in giant cell arteritis and reduce symptoms. You would take it in addition to your usual treatment, and it might help lower the dose of steroids you need.
This trial tests a medicine called upadacitinib (an anti-JAK pill) for people with giant cell arteritis that affects the large arteries, especially the aorta. It is for those whose disease is active despite trying another treatment called tocilizumab, and aims to reduce inflammation and prevent damage.
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
This study looks at immune cells called B-cells in people with giant cell arteritis (a condition causing inflammation in blood vessels) and other immune disorders, to see if targeting these cells could be a new treatment. It involves imaging and blood tests.
This trial compares two different lengths of steroid treatment for giant cell arteritis, an inflammatory blood vessel disease. Participants receive the medication tocilizumab along with either 8 weeks or 26 weeks of prednisone, to see if a shorter course is just as safe and effective.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
Hear when a new Aortitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.